Formula I Compounds Targeting Replicating and Non-Replicating TB Strains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis are inadequate due to the lack of understanding of M. tuberculosis physiology, leading to ineffective chemotherapy and the emergence of drug-resistant strains, necessitating new compounds and therapeutics.
Innovation Solution
Pharmaceutical compositions comprising compounds of Formula I or their pharmaceutically acceptable salts, esters, or prodrugs, which selectively inhibit replicating or non-replicating Mycobacterium tuberculosis, are administered to treat tuberculosis, targeting both forms of the bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat tuberculosis, then treatment can be initiated, but the treatment courses become extremely long and drug-resistant strains emerge
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antitubercular agents through systematic variation of molecular components (R1-R6 substituents, A1-A2 core structure). This chemical parameter modification enables the development of compounds with enhanced potency and reduced treatment duration while maintaining effectiveness against TB strains, directly addressing the contradiction between treatment reliability and duration.
Solution Approach 2:
The invention segments the complex problem of TB treatment by dividing bacterial populations into replicating and non-replicating forms, and develops compounds that can target both forms separately. This segmentation allows for optimized treatment strategies that reduce overall treatment duration while maintaining effectiveness, resolving the contradiction between treatment reliability and duration.
2Reliability
If conventional chemotherapy is used, then treatment can be administered, but multi-drug resistant and totally-drug resistant strains increase
Solution Approach 1:
The patent employs composite material principles by creating novel molecular structures that combine multiple functional groups and structural motifs ( Formula I compounds with specific R1-R6 substituents). These composite molecular designs enable the development of antitubercular agents with new mechanisms of action that bypass existing drug resistance pathways, thereby maintaining treatment effectiveness while reducing the emergence of resistant strains.
Solution Approach 2:
Systematic parameter changes in the chemical structure (varying substituents at positions R1-R6 and the A1-A2 core) generate a diverse library of compounds with different pharmacological properties. This structural parameter variation allows for the identification of compounds with unique binding modes and mechanisms that are less susceptible to resistance development, directly addressing the drug resistance problem.
3Productivity
If a fundamental understanding of M. tuberculosis physiology is achieved, then more effective agents can be discovered, but current lack of understanding prevents this
Solution Approach 1:
The patent applies self-service by designing compounds that autonomously target specific physiological processes of M. tuberculosis without requiring prior detailed knowledge of its mechanisms. The Formula I compounds are designed to interact with essential bacterial targets (such as enzymes or membrane structures) in a way that naturally exploits bacterial physiology, enabling drug discovery to proceed independently of complete physiological understanding.
Solution Approach 2:
The invention uses intermediary compounds (Formula I agents) that serve as mediators between our current limited knowledge and the complex physiology of M. tuberculosis. These compounds are designed to interact with essential bacterial targets in a manner that reveals physiological information through their mechanism of action, thereby facilitating the gradual acquisition of fundamental physiological understanding while simultaneously achieving therapeutic effect.
Data Source
AI summary
Disclosed are compounds that can be used for treating tuberculosis.